Literature DB >> 18197122

Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels.

Edward R Cachay1, Simon D W Frost, Art F Y Poon, David Looney, Sherry M Rostami, Mary E Pacold, Douglas D Richman, Susan J Little, Davey M Smith.   

Abstract

We assessed the effect of herpes simplex virus type 2 (HSV-2) acquisition on the plasma HIV RNA and CD4 cell levels among individuals with primary HIV infection using a retrospective cohort analysis. We studied 119 adult, antiretroviral-naive, recently HIV-infected men with a negative HSV-2-specific enzyme immunoassay (EIA) result at enrollment. HSV-2 acquisition was determined by seroconversion on HSV-2 EIA, confirmed by Western blot analysis. Ten men acquired HSV-2 infection a median of 1.3 years after HIV infection (HSV-2 incidence rate of 7.4 per 100 person-years of follow-up). The median time of follow-up after acquiring HSV-2 infection was 303 days. All men except 1 were asymptomatic during HSV-2 acquisition, and only 1 HSV-2 seroconverter, who was asymptomatic, had a transient increase in blood HIV load (0.5 log10 copies/mL over 11 days). The HSV-2 incidence rate was high in our cohort of recently HIV-infected individuals; however, HSV-2 acquisition did not significantly change the plasma HIV dynamics and CD4 cell levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197122      PMCID: PMC2630881          DOI: 10.1097/QAI.0b013e318163bd87

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

1.  Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2.

Authors:  Rhoda Ashley-Morrow; Elizabeth Krantz; Anna Wald
Journal:  Sex Transm Dis       Date:  2003-04       Impact factor: 2.830

2.  The impact of active herpes simplex virus infection on human immunodeficiency virus load.

Authors:  L Mole; S Ripich; D Margolis; M Holodniy
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

3.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

4.  Protective vaccination against genital herpes simplex virus type 2 (HSV-2) infection in mice is associated with a rapid induction of local IFN-gamma-dependent RANTES production following a vaginal viral challenge.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  Am J Reprod Immunol       Date:  2001-12       Impact factor: 3.886

5.  Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers.

Authors:  W McFarland; L Gwanzura; M T Bassett; R Machekano; A S Latif; C Ley; J Parsonnet; R L Burke; D Katzenstein
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

Review 6.  Innate immunity to herpes simplex virus type 2.

Authors:  Rebecca J Duerst; Lynda A Morrison
Journal:  Viral Immunol       Date:  2003       Impact factor: 2.257

7.  Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.

Authors:  Timothy Schacker; Judith Zeh; Huilin Hu; Mary Shaughnessy; Lawrence Corey
Journal:  J Infect Dis       Date:  2002-11-22       Impact factor: 5.226

8.  Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection.

Authors:  Edward R Cachay; Simon D W Frost; Douglas D Richman; Davey M Smith; Susan J Little
Journal:  J Infect Dis       Date:  2007-03-15       Impact factor: 5.226

9.  Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda.

Authors:  David Serwadda; Ronald H Gray; Nelson K Sewankambo; Fred Wabwire-Mangen; Michael Z Chen; Thomas C Quinn; Tom Lutalo; Noah Kiwanuka; Godfrey Kigozi; Fred Nalugoda; Mary P Meehan; Rhoda Ashley Morrow; Maria J Wawer
Journal:  J Infect Dis       Date:  2003-10-28       Impact factor: 5.226

10.  Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men.

Authors:  T Schacker; A J Ryncarz; J Goddard; K Diem; M Shaughnessy; L Corey
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more
  6 in total

Review 1.  The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.

Authors:  Ruanne V Barnabas; Emily L Webb; Helen A Weiss; Judith N Wasserheit
Journal:  AIDS       Date:  2011-08-24       Impact factor: 4.177

2.  Incidence, prevalence, and epidemiology of herpes simplex virus-2 in HIV-1-positive and HIV-1-negative adolescents.

Authors:  Staci L Sudenga; Mirjam-Colette Kempf; Gerald McGwin; Craig M Wilson; Edward W Hook; Sadeep Shrestha
Journal:  Sex Transm Dis       Date:  2012-04       Impact factor: 2.830

3.  Left out but not forgotten: Should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV?

Authors:  Darrell H S Tan; Rupert Kaul; Sharon Walsmley
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

4.  Seminal Shedding of CMV and HIV Transmission among Men Who Have Sex with Men.

Authors:  Sara Gianella; Konrad Scheffler; Sanjay R Mehta; Susan J Little; Lorri Freitas; Sheldon R Morris; Davey M Smith
Journal:  Int J Environ Res Public Health       Date:  2015-07-07       Impact factor: 3.390

5.  No Role of Herpes Simplex Virus Type 2 (HSV-2) Infection zzm321990on HIV Progression in Naïve HIV Patients

Authors:  Minoo Mohraz; Arezoo Aghakhani; Saeedeh Moayedi-Nia; Mohammad Banifazl; Alireza Janbakhsh; Setareh Mamishi; Afsaneh Karami; Anahita Bavand; Pegah Mirzapour; Amitis Ramezani
Journal:  Iran Biomed J       Date:  2017-07-09

Review 6.  Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Authors:  Darrell Hoi-San Tan; Kellie Murphy; Prakesh Shah; Sharon Lynn Walmsley
Journal:  BMC Infect Dis       Date:  2013-10-28       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.